SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release: SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma08-12-2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release: SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox PharmaSUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release: "SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target."Sun Pharma Advanced Research Company Ltd - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per Letter attachedSUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per letter attachedSUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release: SPARC to Provide Update on Clinical Programs and R&D Pipeline.Sun Pharma Advanced Research Company Ltd - 532872 - Statement On Deviation Or Variation In The Use Of Proceeds Of Preferential Issue
As per letter attached.SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Statement On Deviation Or Variation In The Use Of Proceeds Of Preferential Issue
As per letter attached.SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of The Board Meeting Held Today I.E. November 01, 2021
As per Letter attachedSun Pharma Advanced Research Company Ltd - 532872 - Board Meeting Intimation for Consideration Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2021 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2021